秋水仙碱用于脓毒症(COLINS):一项随机双盲安慰剂对照试验的研究方案
这是一项在伊朗大不里士Imam Reza医院开展的前瞻性、双盲、安慰剂对照随机试验方案,计划纳入44例18至80岁脓毒症患者,按1:1随机接受秋水仙碱1 mg每日或安慰剂治疗10天,主要结局为基线至第4天白细胞介素-6(IL-6)的变化。
要点
- COLINS试验将首次研究秋水仙碱对比安慰剂在脓毒症患者中的疗效。
- 44例脓毒症患者按1:1随机接受秋水仙碱1 mg每日或安慰剂治疗10天。
- 主要结局为基线至第4天IL-6变化,并评估SOFA与qSOFA评分及呼吸循环支持需求。
核心结论
- COLINS试验将首次研究秋水仙碱对比安慰剂在脓毒症患者中的疗效,其结果将推动脓毒症治疗向前迈进。
研究设计与样本
- 这是一项前瞻性、双盲、安慰剂对照随机试验,在伊朗大不里士的Imam Reza医院开展。
- 计划纳入44例18至80岁确诊脓毒症的患者,按1:1随机接受秋水仙碱1 mg每日或安慰剂治疗10天。
主要发现
- 实验研究提示秋水仙碱在动物脓毒症模型中具有有益作用,但其在脓毒症临床中的效应尚未被研究。
关键数值与推荐
- 主要结局为基线至第4天白细胞介素-6(IL-6)的变化。
- 将在基线、第4天和第10天评估序贯器官衰竭评估(SOFA)和qSOFA评分。
- 将从随机化至第4天和第10天评估患者对补充氧、机械通气和血管升压药的需求。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is a life-threatening condition with high mortality rates of up to 40% due to multiple organ dysfunction. Systemic inflammatory response plays a key role in the pathophysiology and progression of this disease. Therefore, anti-inflammatory drugs can be considered as augmentation therapy for the management of the early phase of inflammation in septic patients, along with appropriate antimicrobial therapy and source control. Experimental studies suggest the beneficial effects of colchicine in animal septic models. However, the clinical effects of colchicine in the setting of sepsis have not been investigated yet. METHODS: This prospective, double-blinded, placebo-controlled, randomized trial will be conducted at Imam Reza Hospital, the largest northwest referral hospital, in Tabriz, Iran. A total of 44 patients aged 18 to 80 years with sepsis diagnosis will be randomized 1:1 to receive colchicine 1 mg daily or placebo for 10 days. The primary outcome is interleukin-6 (IL-6) changes from the baseline through day 4. Sequential organ failure assessment (SOFA) and qSOFA scores will be evaluated at baseline, day 4, and day 10. Patients will be assessed regarding the need for supplemental oxygen, mechanical ventilation, and vasopressor from the randomization through day 4 and day 10. DISCUSSION: The Colchicine IN Sepsis (COLINS) trial will be the first to investigate colchicine's efficacy versus placebo in sepsis patients. The results of this trial will be a step forward in treating patients with sepsis. TRIAL REGISTRATION: Clinical trial ID: IRCTID: IRCT20231017059748N1. Registration date: 21 October 2023. https://irct.behdasht.gov.ir/trial/73232 .
引用
- Pourkarim F, Mahmoodpoor A, Soleimanpour H, et al. The effect of Colchicine IN Sepsis (COLINS): a study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2025. PMID: 40544304. doi:10.1186/s13063-025-08901-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。